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Abstract
To characterize mitochondrial/apoptotic parameters in chronically human immunodeficiency virus (HIV-1)-infected promonocytic and lymphoid
cells which could be further used as therapeutic targets to test pro-mitochondrial or anti-apoptotic strategies as in vitro cell platforms to deal
with HIV-infection. Mitochondrial/apoptotic parameters of U1 promonocytic and ACH2 lymphoid cell lines were compared to those of their unin-
fected U937 and CEM counterparts. Mitochondrial DNA (mtDNA) was quantified by rt-PCR while mitochondrial complex IV (CIV) function was
measured by spectrophotometry. Mitochondrial-nuclear encoded subunits II–IV of cytochrome-c-oxidase (COXII-COXIV), respectively, as well
as mitochondrial apoptotic events [voltage-dependent-anion-channel-1(VDAC-1)-content and caspase-9 levels] were quantified by western blot,
with mitochondrial mass being assessed by spectrophotometry (citrate synthase) and flow cytometry (mitotracker green assay). Mitochondrial
membrane potential (JC1-assay) and advanced apoptotic/necrotic events (AnexinV/propidium iodide) were measured by flow cytometry. Signifi-
cant mtDNA depletion spanning 57.67% (P < 0.01) was found in the U1 promonocytic cells further reflected by a significant 77.43% decrease
of mitochondrial CIV activity (P < 0.01). These changes were not significant for the ACH2 lymphoid cell line. COXII and COXIV subunits as well
as VDAC-1 and caspase-9 content were sharply decreased in both chronic HIV-1-infected promonocytic and lymphoid cell lines (<0.005 in most
cases). In addition, U1 and ACH2 cells showed a trend (moderate in case of ACH2), albeit not significant, to lower levels of depolarized mito-
chondrial membranes. The present in vitro lymphoid and especially promonocytic HIV model show marked mitochondrial lesion but apoptotic
resistance phenotype that has been only partially demonstrated in patients. This model may provide a platform for the characterization of HIV-
chronicity, to test novel therapeutic options or to study HIV reservoirs.
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Introduction
Data regarding the potential role of mitochondria in the
cytopathogenicity of human immunodeficiency virus (HIV) have led to
great interest in the study of the relationships between these two enti-
ties [1]. Mitochondria have been closely linked to HIV infection, as a
target of the deleterious effects of both HIV [2] and antiretroviral ther-
apy (ART) [3] in relation to their involvement in the development of
apoptosis. Mitochondrial and apoptotic alterations have been widely
described in both na€ıve and treated patients in vivo [4, 5].
Human immunodeficiency virus has tropism for hematopoietic
cells [6]. This lentivirus is able to infect either lymphocytes or mono-
cytes and macrophages, but the latter cells do not seem to undergo
apoptosis following infection and represent a potential viral reservoir
[7]. Mitochondrial and apoptotic lesions in both lymphocytes and
monocytes have been associated with accelerated HIV progression in
na€ıve patients [8, 9] and in peripheral tissues from treated patients as
a result of secondary effects of medication [10]. A positive correlation
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has been described between apoptosis in peripheral blood lympho-
cytes and monocytes and the severity of HIV infection [11].
Whether mitochondrial and apoptotic malfunctions are causal
factors rather than a consequence of differential HIV progression
patterns remains to be elucidated. It is still unknown whether ade-
quate mitochondrial function contributes to preventing mitochon-
drial-driven apoptosis of the defence cells, increasing the organism
defences against a specific viral antigen. It would be conceivable
that correct mitochondrial function protects defence cells to
undergo apoptosis, which, in turn, would slow down the infective
capacity of HIV progression.
The interaction between mitochondria, apoptosis and HIV has
been well-described in HIV-infected patients [12, 13] and several
groups including ours, have assessed the association between mito-
chondrial and apoptosis alterations and the severity of HIV infection
[8, 9, 14]. Nevertheless, there is very little information on adequate
mitochondrial characterization of in vitro models of HIV infection. Dif-
ferent animal models such as primate models have been used to fur-
ther explore the disease and/or its treatment [15]. However, high
ratios of cost/effectiveness requiring complex facilities have been
associated with these models. Cell models could contribute to solve
these disadvantages. In this study, we used two different types of cell
models which represent the main target cells for HIV (monocytes and
lymphocytes). Human immunodeficiency virus-1-infected U1 and
ACH2 cell lines are, respectively, promonocytic and lymphoid cell
lines derived from uninfected U937 (same U1 cell line but uninfected)
and CEM (same ACH2 cell line, but uninfected) precursor cells. U1
and ACH2 lines are characterized by harbouring one and two stable
integrated copies of the HIV-1 genome which replicates at a low rate,
comparable to slow progression of the infection in patients. In these
cell lines, HIV-1 latently auto-replicates itself, constituting a world-
wide model to study chronic HIV infection [16, 17]. One previous
study has shown apoptotic resistance involving modulation of the
apoptotic mitochondrial pathway in persistently infected HIV-1 cells
[18], however, accurate characterization of mitochondrial mecha-
nisms and mitochondrial-derived apoptosis has yet to be performed
in these models of chronically infected cells.
The hypothesis of this study was that the mitochondrial and
apoptotic damage initiated by HIV infection may contribute to the
persistence of infection chronicity and progression. As a proof-of-
concept, we expected mitochondrial genetics, function, expression
and apoptotic levels to be altered in both chronically HIV-1-
infected promonocytic and lymphoid cell lines. These parameters
were initially determined in the chronically HIV-1-infected
promonocytic and lymphoid cell lines U1 and ACH2, being U937
and CEM non-HIV-infected cells used as in vitro cellular controls
respectively. Mitochondrial and apoptotic involvement in the pro-
gression of HIV infection could lead to the use of putative mito-
chondrial or apoptotic therapeutic strategies to deal with the
chronicity of HIV patients.
In depth characterization of the mitochondrial and apoptotic path-
ways in these cell models may lead to elucidate whether these in vitro
models resemble in vivo alterations observed in patients, providing a
platform to test potential targets (such as mitochondrial or apoptotic
therapeutic targets) to fight HIV infection.
Materials and methods
Cell lines
Chronically infected HIV-1 promonocytic (U1) and lymphoid (ACH2) are
cloned cell lines derived by limiting dilution cloning of U937 or CEM
cells surviving an acute infection with HIV-1 (LAV-1 strain) first gener-
ated by Folks et al. [19, 20].
U1 and ACH2 cell lines, as well as their non-HIV-infected counter-
parts U937 and CEM, respectively, were cultured at 37°C in a fully
humidified atmosphere with 5% CO2 in RPMI-1640 medium (BioWhit-
taker, LONZA Portsmouth, NH, USA) supplemented with 10% foetal calf
serum, and 1% penicillin-streptomycin, by trained personnel in P3 facil-
ity cores devoted to viral replication.
Mitochondrial and apoptotic parameters and experimental setups
were simultaneously evaluated in these HIV-1-infected cell lines and
their corresponding uninfected controls, and were run in parallel with
both infected and control cell lines. Cell cultures were grown into 12
experiments (including four lines in parallel). Experimental measure-
ments were run, at least, in triplicates.
Mitochondrial DNA depletion through multiplex
real time PCR
A mitochondrial DNA (mtDNA) depletion study was performed as
described. Total DNA was phenol-chlorophorm-extracted, spectrophoto-
metrically quantified and diluted at 5 ng/ll. Multiplex real-time PCR
(PCR Applied Biosystems (Foster City, CA, USA) 7500 Real Time PCR
System) was performed with 96 round bottom well plates with the
simultaneous determination of the mitochondrial 12S ribosomal RNA
(mt12SrRNA) gene and the constitutive nuclear RNAseP gene (nRNA-
seP). The former used mtF805 (50-CCACGGGAAACAGCAGTGAT-30) and
mtR927 (50-CTATTGACTTGGGTTAATCGTGTGA-30) with the TaqMan
Probe 6FAM-50-TGCCAGCCACCGCG-30-MGB (Sigma-Aldrich, St. Louis,
MO, USA). The latter used a commercial kit (4304437; Applied Biosys-
tems). Each well included 25 ng of total genomic DNA diluted in 20 ll
total reaction mixture containing: 19 TaqMan Universal PCR Master
Mix (ABI P/N 4304437), 1 ll RNAseP commercial kit and 125 nM of
each mtDNA primer and 125 nM of mtDNA probe.
The PCR was set at 2 min. at 50°C, 10 min. at 95°C, followed by 40
cycles each of 15 sec. of denaturalization at 95°C and 60 sec. of
annealing/extension at 60°C. The mt12SrRNA gene was normalized by
determining the nRNAseP nuclear gene and expressed as mt12SrRNA/
nRNAseP ratio.
Mitochondrial function by enzymatic activities
Complex IV (CIV) enzymatic activity was measured as an experimental
parameter [21] representative of mitochondrial function. The enzymatic
activity of CIV was measured following national standardization rules of
the Spanish network for the study of mitochondrial respiratory chain
(MRC) enzyme activities. This enzymatic assay was spectrophotometri-
cally measured at 37°C at a wavelength of 550 nm including an internal
control of pig muscle sample with known reference values and
expressed as nmols/min.mg protein.
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Protein subunits content and mitochondrial
apoptotic events by western blot
Mitochondrial and nuclear DNA encoded subunits (COXII and COXIV,
respectively) of CIV, in addition to voltage-dependent anion chanel-1
(VDAC-1) and caspase-9 content were analysed by western blot. In
brief, 20–30 lg crude cell lysates were mixed 1:5 with a solution con-
taining 50% glycerol, 10% SDS, 10% b-mercapto-ethanol, 0.5% bro-
mophenol blue and 0.5 M Tris (pH 6.8), incubated at 99°C for 5 min.
for protein denaturalization and electrophoresed on 0.1% SDS ranging
from 7% to 13% of polyacrylamide gels. Proteins were transferred
onto nitrocellulose membranes for 7 min. using an automatic system.
Blots were probed with (i) a monoclonal antibody (moAb) recognizing
the mtDNA-encoded human COXII subunit as a marker of the mito-
chondrial protein synthesis rate (A6404; Molecular Probes, Eugene,
OR, USA), (ii) a moAb elicited against the nuclear DNA encoded
human COXIV subunit as a marker of the nuclear protein synthesis
rate (A21347; Molecular Probes) and (iii) an anti-b-actin moAb
(A5441; Sigma-Aldrich) as a loading control of overall cell protein
content. The protein subunits content was normalized by the content
of b-actin signal to establish the relative abundance per overall cell
protein. Antimouse and anti-rabbit secondary antibodies were used
depending on the primary antibody [22]. Mitochondrial and nuclear
protein synthesis ratios were expressed, respectively, as COXII/b-actin
and COXIV/b-actin.
Apoptosis approaches were measured by western blot (as aforemen-
tioned) using the moAb raised against VDAC-1 (529536, antiporin
31HL; Calbiochem, Darmstadt, Alemania) as a marker of early apoptotic
mitochondrial events and moAB against caspase-9 (ab2324; Abcam,
Cambridge, UK) as marker of advanced apoptotic mitochondrial events,
normalized by b-actin content and expressed as the VDAC-1/b-actin and
caspase-9/b-actin ratios.
Mitochondrial content quantified by citrate
synthase enzymatic activity
Citrate synthase (CS) enzymatic activity was measured as a reliable
marker of mitochondrial content [21]. Enzymatic activity was spec-
trophotometrically measured following national standardization rules of
the Spanish network for the study of MRC enzyme activities. This enzy-
matic assay was performed at 37°C including an internal control of pig
muscle sample with known reference values and assessed at a wave-
length of 412 nm and expressed as nmols/min.mg of protein.
Mitochondrial content, mitochondrial
depolarization and advanced apoptosis/necrosis
by flow cytometry
Mitochondrial content was determined by mitotracker green (MTG), and
mitochondrial membrane potential (MMP) was estimated by JC-1 stain-
ing as reported elsewhere [23, 24] in cell lines either in the presence or
absence of the mitochondrial pro-apoptotic and depolarizing stimuli vali-
nomycin. Advanced apoptosis and necrosis phenomena were assessed
using the annexin V and propidium iodide (PI) ratio by means of flow
cytometric analysis. Briefly, a total of 1 ml of complete culture media
containing roughly 2 9 105 cells was prepared for different reaction
procedures and subjected to incubation: (i) in the absence of any dye
used for the autofluorescence calculation, (ii) with 200 nM MTG fluo-
rophore (M-7514; Molecular Probes) for 30 min. for mitochondrial con-
tent quantification, (iii) with 0.02% JC1 dyer (T-3168; Molecular
Probes) for 10 min. for MMP assessment, (iv) with 0.02% JC1 fluo-
rophore plus 0.05% valinomycin pro-apoptotic and depolarizing stimuli
reagent (60403; Sigma-Aldrich) for 10 min. and (v) with 0.05% annexin
V plus PI (556463; BD Biosciences, East Rutherford, NJ, USA) for
10 min. to assess advanced apoptotic and necrotic events. All cytomet-
ric analyses were performed in a FACScalibur cytometer with an argon
ion laser tuned at 488 nm and a diode laser tuned at 635 nm (Becton
Dickinson, San Jose, CA, USA). Results were expressed as median or
percentage of cells with specific fluorescence.
Statistics
Results were expressed as mean  S.E.M. Descriptive statistics were
performed using the Statistical Package for the Social Sciences (SPSS)
software (IBM inc. SPSS Statistics Chicago, IL, USA). A single filter was
applied to discard extreme values. Statistical analysis was performed
with non-parametric Kruskal–Wallis H and Mann–Whitney U-tests, and
the level of significance was considered at P < 0.05 (for a confidence
interval of a = 95%).
Results
Mitochondrial DNA content showed a significant decrease in the
promonocytic latently infected HIV-1 cell line U1 compared to its
respective uninfected U937 control cell line (204.64  28.07 versus
483.34  97.61; P < 0.01). However, the lymphoid latently infected
HIV-1 cell line ACH2 showed non-significant variations of mtDNA
content compared to the uninfected CEM control cells
(227.32  42.99 versus 162.59  22.35, P = NS; Fig. 1).
Mitochondrial CIV enzymatic activity was then quantified. In
agreement with the above results, CIV enzymatic activity significantly
decreased in infected promonocytic U1 cells with respect to unin-
fected U937 control cells (10.57  2.46 versus 46.84  7.30,
P < 0.01). On the other hand, this value remained non-significantly
altered, although showing a trend to decrease in the infected ACH2
lymphoid cell line compared to uninfected CEM control cells
(17.86  6.12 versus 24.16  3.45, P = NS; Fig. 2).
Thereafter, the content of mitochondrial protein subunits was
assessed by the expression of both the mtDNA-encoded COXII
(Fig. 3A) and the nuclear encoded COXIV (Fig. 3B), components of
the MRC CIV. The expression of these two subunits was reduced in
both chronically HIV-1-infected cell lines studied compared to their
respective uninfected control cell lines (U1 versus U937 and ACH2
versus CEM, P < 0.001 in all cases).
Moreover, early and advanced apoptotic mitochondrial events
estimated as VDAC-1 and caspase-9 content, respectively, were sig-
nificantly reduced in infected U1 and ACH2 infected cell lines versus
their respective uninfected counterparts (U937 and CEM, respectively,
P < 0.05 in all cases, except for caspase-9 in lymphoid cell lines:
P = 0.079; Fig. 4A and B).
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The mitochondrial content did not show any statistically signifi-
cant differences, quantified by either CS activity (Fig. 5) or by the
MTG assay (data not shown).
Finally, the comparisons with mitochondrial membrane depolar-
ization in addition to advanced apoptosis and the necrosis markers
assessed by flow cytometry did not reach statistical significance,
although some parameters showed a bias. Thereby, the U1 promono-
cytic infected cell line showed a trend to lower levels of depolarized
mitochondria than their uninfected U937 control cells, although these
differences were not statistically significant (0.22  0.16 versus
2.38  2.38 respectively). This trend was slight in the HIV-1-infected
ACH2 lymphoid cell line versus uninfected CEM cells (9.99  9.74
versus 12.44  10.85, P = NS). The formerly described increment
pattern was also exhibited in promonocytic U1 infected cells versus
U937 uninfected control when cells were exposed to a pro-apoptotic
reagent (valinomycin) (1.54  1.54 versus 10.22  10.22, respec-
tively), but this exacerbation pattern was not observed in ACH2 lym-
phoid cells versus uninfected control CEM cells (13.72  11.51
versus 12.91  10.88 respectively).
The rate of cells of either promonocytic or lymphoid origin under-
going apoptosis or necrosis measured by annexin V plus PI did not
render significant differences. A trend towards a decrease was
observed in HIV-1-infected U1 promonocytic cells with respect to
their U937 controls (9.92 versus 27.63 respectively), whereas an
increase was observed in HIV-1-infected ACH2 lymphoid cells in com-
parison with their CEM control cells (23.40 versus 4.32).
Discussion
In this study, we compared mitochondrial and apoptotic parameters
in chronically HIV-1-infected promonocytic and lymphoid cell lines
with their uninfected counterparts to evaluate whether they could be
used as HIV infection models of the in vivo mitochondrial and apop-
totic lesion characteristic of HIV-infected patients. Most of the mito-
chondrial and apoptotic parameters were altered in the HIV-infected
cell lines, especially in the promonocytic lineage, resembling in vivo
alterations in case of mitochondrial findings. However, contrarily to
what is observed in vivo, both promonocytic and lymphoid HIV-
infected models showed resistance to undergo apoptosis. In the case
of the promonocytic infected cell line U1, this may lead to a useful
model to study HIV reservoirs, frequently established in these cell lin-
eages. However, in vivo apoptosis of lymphocytes followed by infec-
tion was not observed in the ACH2 model, except for the trends of
annexin V and PI measured by flow cytometry.
Mitochondrial and apoptotic abnormalities have been postulated
to be the basis of collateral effects such as the development of hyper-
lactatemia, lipodystrophy and neuropathy associated with both HIV
infection and its treatment [25–28]. Although most mitochondrial
changes are considered to be the result of HIV apoptotic capacity and
the secondary effects derived from ART [12], there is a growing evi-
dence of the crucial role of mitochondria in the dynamics of HIV infec-
tion [29]. Despite the interest in several areas of the HIV infection
process such as HLA, polymorphisms in viral co-receptors,
Fig. 2 CIV enzymatic activity. This figure shows the enzymatic activity of complex IV of the mitochondrial respiratory chain of promonocytic (left)
and lymphoid (right) cell lines expressed in nmols/min mg protein. A significant decrease in complex IV activity was observed in the infected
promonocytic cell line U1 with respect to its uninfected U937 control, P < 0.01. NS: not significant.
Fig. 1mtDNA content. This figure shows the mtDNA versus nuclear DNA ratio (expressed in arbitrary units) in the infected promonocytic U1
cell line with respect to its uninfected U937 control (left), P < 0.01, as well as in the HIV-1-infected lymphoid ACH2 cell line with respect to
its CEM control (right), P = NS. MtDNA: mitochondrial DNA, Mt12SrRNA: mitochondrial 12SrRNA ribosomal gene, nRNAseP: nuclear RNAseP
gene, NS: not significant.
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antibodies, chemokines and defensins, among others [30, 31], the
role of mitochondria has become outstanding in this process [29,
32].
The mitochondrial and apoptotic damage induced by HIV infection
may exacerbate these deleterious effects in a kind of vicious cycle,
terminating in the loss of cell defence capability of the host and the
progression of infection. Studies performed to date have highlighted
the need to establish an in vitro model to further investigate possible
therapeutic approaches to revert mitochondrial or apoptotic damage
and determine novel tools to fight HIV progression.
Mitochondrial parameters
In our cell models, most of the mitochondrial parameters were
affected in both cell lines. Mitochondrial genome content and func-
tional enzymatic activity were sharply depleted in U1 promonocytic
cells, without being significantly modified in the ACH2 lymphoid cells.
Both infected cell lines exhibited a marked decrease in MRC subunit
expression which, in case of the promonocytic cells, goes in agree-
ment with the outstanding dysfunction of the MRC. The expression of
mitochondrial protein subunits of MRC was above 90% decreased in
most cases compared to their uninfected counterparts. These
mitochondrial and nuclear encoded subunits were diminished in both
HIV-1-infected cell lines, suggesting both mitochondrial and nuclear
gene malfunctions in all cases.
Apoptotic parameters
A link between HIV infection and apoptosis has been widely reported
[33]. Some viral proteins interact with mitochondrial targets, leading
to apoptosis through different pathways [34, 35]. This is the case of
the viral protein R (Vpr), the HIV-1-trans-activating protein (Tat) and
the viral protease (Pr), which can directly interact with components of
the mitochondrial permeability transition pore (Vpr interacts with the
adenine nucleotide translocator ANT attached to VDAC, thus prompt-
ing mitochondrial depolarization) [32], translocate proapoptotic pro-
teins into the mitochondria (Tat mediates Bim translocation) [33],
activate caspases (Vpr activates caspases 3 and 9) [34] or inactivate
anti-apoptotic proteins (Vpr inactivates HAX-1 and Pr inactivates Bcl-
2) [34, 35], ultimately causing cell death. Consequently, the marked
significant decrease in the early and advanced apoptotic markers
(VDAC-1 and caspase-9 proteins) in both infected cell lines studied
was unexpected. These results are in agreement with the lower levels
of early apoptotic events of depolarized mitochondrial membranes
observed with JC1 by flow cytometry in both infected U1 and ACH2
cell lines, although such trends did not achieve statistical significance.
Fig. 3 (A) COXII content. This figure shows COXII protein subunit content in arbitrary units with expression of the levels of mitochondrial DNA
encoded subunit II of complex IV of promonocytic (left) and lymphoid (right) cell lines normalized by b-actin content. A significant decrease in mito-
chondrial protein synthesis was observed in promonocytic and lymphoid U1 and ACH2 infected cell lines with respect to their uninfected U937 and
CEM controls. COX: cytochrome c oxidase, AU: arbitrary units. (B) COXIV content. This figure shows COXIV protein subunit content in arbitrary units
with expression of the levels of nuclear DNA encoded subunit IV of complex IV of promonocytic (left) and lymphoid (right) cell lines normalized by
b-actin content. A significant decrease in nuclear protein synthesis was observed in promonocytic and lymphoid U1 and ACH2 infected cell lines
with respect to their uninfected U937 and CEM controls. COX: cytochrome c oxidase, AU: arbitrary units.
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Our data strongly indicate that latently infected cells are less suscepti-
ble to undergo apoptosis compared to uninfected cells. These results
support a previous study [18] which was mainly focused on the reac-
tion of specific cell lines against different exogenous pro-apoptotic
and stress-induced stimuli. Although HIV infection most frequently
leads to cell death, the latently HIV-1-infected cell lines studied only
showed a reduced apoptotic behaviour which may be indicative of a
viral strategy to survive [36]. In this sense, both promonocytic and
lymphoid HIV-1-infected cell lines showed different patterns in
advanced apoptosis and necrosis phenomena tested by flow cytome-
try through annexin V plus PI staining. A trend to decrease in
advanced apoptotic events was observed in the infected U1
promonocytic cell lines compared to their controls, whereas a ten-
dency to increase was observed in infected ACH2 lymphoid cell lines.
These data are also in agreement with the lower sensitivity to apopto-
sis previously observed in promonocytic versus lymphoid cells [37].
Validation of both in vitro models
Considering all these results, our findings suggest that these cell
models may at least partially reproduce in vitro the alterations
observed in vivo in HIV-infected patients [4, 8, 9, 12, 13] that should
be further characterized in depth.
Fig. 4 (A) VDAC-1 content. This figure shows the VDAC-1 content expressed in arbitrary units. The expression of the levels of VDAC-1 content nor-
malized by b-actin of promonocytic (left) and lymphoid (right) cells. A significant decrease in early mitochondrial apoptosis was observed in
promonocytic and lymphoid U1 and ACH2 infected cell lines with respect to their uninfected U937 and CEM controls. VDAC-1: voltage-dependent
anion channel-1, AU: arbitrary units. (B) Caspase-9 content. This figure shows the caspase-9 content expressed in arbitrary units. The expression of
the levels of caspase-9 content normalized by b-actin of promonocytic (left) and lymphoid (right) cells. A decrease in advanced mitochondrial apop-
tosis was observed in promonocytic (significant) and lymphoid (non-significant) U1 and ACH2 infected cell lines with respect to their uninfected
U937 and CEM controls. AU: arbitrary units.
Fig. 5Mitochondrial content. This figure shows the mitochondrial content measured by citrate synthase enzymatic activity expressed in nmols/min
mg protein of promonocytic (left) and lymphoid (right) cells. No significant changes were observed in infected promonocytic and lymphoid U1 and
ACH2 cell lines with respect to their uninfected U937 and CEM controls. NS: not significant.
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
407
J. Cell. Mol. Med. Vol 21, No 2, 2017
From a mitochondrial point of view, both promonocytic and lym-
phoid cell lines showed pronounced abnormalities with slightly differ-
ent patterns. Previous studies reported different behaviour for
promonocytic and as well as lymphoid cell lines [37] or monocytes/
lymphocytes [36] suggesting that different molecular mechanisms
may depend on cell types considered. In our study, although both
promonocytic and lymphoid cell lines showed changes in MRC
expression, only the promonocytic cells (not the lymphoid lineage)
showed significant alterations at the mitochondrial genetic and func-
tional levels. In this context, it was surprising to notice the significant
reduced content of subunits COXII and COXIV in the lymphoid
infected lines despite the trends towards increased levels of mtDNA
and only slightly reduced enzymatic activity of the complex IV. It
would be conceivable that, despite the decrease in the subunit protein
levels is observed, the threshold to observe a defective functionality
of the enzyme had not been yet reached, probably due to the homeo-
static up-regulation of mtDNA content in these cells. All these mecha-
nisms were not observed in promonocytic infected cell lines, which
showed decreased ratios in all genetic, functional and expression
mitochondrial parameters fully resembling in vivo conditions.
From the apoptotic point of view, both infected cell lines showed a
trend to a resistance to apoptotic events.
A previous study reported lower MMP in peripheral blood
mononuclear cells from HIV patients, as well as higher apoptotic/
necrotic events in these cells [35]. In this study non-significant trends
were found in MMP. In addition, most of apoptotic/necrotic parame-
ters measured (mitochondrial pore and caspase-9 activation or phos-
phatidylserine expression and nuclear DNA fragmentation) yielded to
similar results suggesting the resistance to undergo apoptosis of
HIV-infected cell models [18, 33] and, as opposite as in vivo condi-
tions of blood cells not becoming reservoirs [4, 5].
Our findings point out the use of the present in vitro models as lar-
gely useful for mitochondrial monitoring. We encourage other
researchers to explore in depth apoptotic events in this and other
in vitro models. Importantly, our results clearly mimic the in vivo mito-
chondrial features of HIV infection, (especially in the promonocytic cell
line), rather than the in vivo apoptotic conditions. Apoptotic resistance
in infected lines might be derived from the genetic modification of the
cancerous lineages that do not undergo apoptosis following viral gen-
ome insertion. Promonocytic apoptotic resistance may reflect the
in vivo percentage of monocytes capable to constitute reservoirs and,
subsequently, become more resistant to apoptosis. Resistance to
apoptosis of ACH2 lymphoid cell line should be taken with caution
when willing to reproduce in vivo pathophysiology of HIV infection. The
observed findings, suggest that such alterations might have HIV clini-
cal consequences as previously described in vivo [11] and point out to
the involvement of mitochondrial status in HIV progression and
chronicity. In addition, this study provides complementary data to the
apoptosis approaches previously considered [15].
In spite of strained HIV-1 replication in the infected cell lines used
in this study, the assessment of the mitochondrial and apoptotic
parameters investigated led to the description of significant changes
compared to the respective uninfected control cell lines. It remains
unknown whether these disturbances would be increased in activated
HIV-1-infected cell lines (with the addition of HIV replication inducer
factors).
A limitation of this study was the resistance to apoptosis of the
cancerous infected cell lines, which remain viable regardless of HIV
infection and would have died in natural conditions. Nonetheless,
despite these limitations, due to the same cancerous origin of both
control and infected lines, it is presumable that the significant
changes found between cell lines are comparable and attributable to
the infection itself. Thereby, we consider that the models studied may
constitute adequate in vitro models to monitorize the patient dynam-
ics at apoptotic and especially at mitochondrial level.
In summary, this study provides evidence that the mitochondrial
and, in a lesser extent, apoptotic pathways are seriously affected in
latently infected HIV-1 promonocytic and lymphoid cells. The avail-
ability of an in vitro HIV model is essential for translational research.
Studies using these cell models of HIV infection may lead to the
development of novel therapeutic tools [38], including apoptotic and
mitochondrial targets [39], as strategies to reverse the lesions
exerted by the virus.
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